su011248

Fatigue

Case Comprehensive Cancer CenterN/ADormant

D

30/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 15/ 100
Competitive Position: 95/ 100

Competitive context

4 Active assets in the Fatigue cohort.

Asset / Sponsor	Phase	Rating
Nuvastatic Natureceuticals Sdn Bhd	Phase 3	BB
Sra-333 Wake Forest University Health Sciences	Phase 2	B
(D)-LIMONENE Pure Green	Phase 2	CCC
PALMITIC MONOETHANOLAMIDE Pure Green	Phase 2	CCC
Mitoquinol mesilate VA Office of Research and Development	Phase 1/2	CCC

View all 12 →

Same molecule, other indications

su011248 is also rated in:

Gastrointestinal Stromal TumorsDormant

BBB

Indicative ·

75 / 100

Pancreatic Neuroendocrine TumorDormant

BB

Indicative ·

69 / 100

Renal Cell CarcinomaDormant

BB

Indicative ·

69 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.